BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.07 (+2.07%)

Company Metrics

  • P/E 0
  • P/S 5.39
  • P/B 8.97
  • EPS -0.69
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / N/A %
  • Avg. Vol. 1.25M
  • Shares 73.69M
  • Market Cap. 254.24M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


HC Stocks Growth: TG Therapeutics Inc (NASDAQ:TGTX), BioCryst Pharmaceuticals ...
share market updates (press release) - 4 hours ago
Shares of TG Therapeutics Inc (NASDAQ:TGTX) ended Friday session in green amid volatile trading. The shares closed up +0.51 points or 7.06% at $7.73 with 843,587.00 shares getting traded.
Biotech Companies To Look Out For: BioCryst Pharmaceuticals (BCRX), Achillion ...
Zergwatch - 2 hours ago
BioCryst Pharmaceuticals, Inc. (BCRX) ended last trading session with a change of 0.6 percent. It trades at an average volume of 1.25M shares versus 0.83M shares recorded at the end of last trading session.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) take heat post earnings
CWRU Observer - May 27, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported earnings for the three months ended Mar2016 on May 05, 2016. The company earned $-0.31 per share on revenue of $4.82M.
How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Analysts Are Bullish? - The Post
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Closes At $3.36 - Markets Daily
After Last Week What Do Analysts Think Of BioCryst Pharmaceuticals, Inc ...
Share Trading News - May 30, 2016
05/06/2016 - BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 10 price target on the stock.
HC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following ...
Smarter Analyst - May 6, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.
BioCryst Pharmaceuticals Inc. (BCRX) Drops 7.41% on May 04 - Equities.com
BioCryst Pharmaceuticals, Inc. (BCRX) Set to Announce Earnings on Thursday - Web Breaking News
Hold Calls Count For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) At 5
Vanguard Tribune - May 29, 2016
Buy calls count on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s stock stands at 0 while Sell recommendations is 1. Hold recommendation is 5. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has a total of 3 Strong Buy recommendations and 0 Strong ...
Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical ...
Smarter Analyst - Feb 8, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary ...
Is BioCryst Reaching Crush Depth? - 24/7 Wall St.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial for HAE - Bidness ETC
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) increased 0.60%: Catalyst ...
Benchmark Monitor - 5 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at The Jefferies 2016 Healthcare Conference in New York on Thursday, June ...
BioCryst Pharmaceuticals, Inc. (BCRX) has potential to increase 313 percent
CWRU Observer - Apr 26, 2016
BioCryst Pharmaceuticals, Inc. (BCRX) has just caught the analyst's attention after adding 5.22 percent in the last trading session.
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
BioCryst Pharma (BCRX) Completes OPuS-2 Enrollment - StreetInsider.com